Phenylethylamine (PEA)

Phenylethylamine (PEA) has been studied for decades in depression, psychosis, and Tourette syndrome. The findings are inconsistent, and measuring it in urine has not been shown to diagnose these conditions, select treatment, or improve long-term health outcomes.

This is an exploratory biomarker. Laboratories can measure the chemical, but there are no widely accepted disease cutpoints or treatment targets for this urine result. A laboratory flag and a psychiatric diagnosis are different things.

What Your Body Makes

Your body makes PEA from phenylalanine. Phenylalanine is an amino acid supplied by dietary protein. PEA occurs in small amounts in the brain and elsewhere in the body, which is why it belongs to a group called trace amines.

Experiments in cultured cells and brain tissue from mice and rhesus monkeys show that PEA can alter the release and recycling of dopamine and norepinephrine. These chemicals help nerve cells communicate. The experiments support a possible role in regulating nerve signals, but they do not establish what your urinary PEA means for your mood or alertness.

PEA is broken down rapidly, largely through monoamine oxidase B (MAO-B). This enzyme starts a process that produces phenylacetic acid (PAA). However, PAA also comes from other routes of phenylalanine breakdown. Human experiments found that changing PEA production or breakdown did not consistently change urinary PAA, so PAA cannot be treated as a direct measure of PEA production.

What This Urine Result Represents

This test measures phenylethylamine in urine by liquid chromatography with mass spectrometry (LC-MS). The method separates chemicals and identifies them using mass-related signals. The catalog reports the result in mcg/g, but it does not identify what the gram refers to or whether PEA attached to other molecules is included. The laboratory's assay documentation needs to clarify those details.

Many older studies measured free PEA in urine collected over 24 hours, using fluorescence assays or gas chromatography. Some reported daily excretion and others adjusted results for urine creatinine. These findings provide historical context, but their numerical results cannot be transferred directly to this LC-MS assay.

A urinary measurement combines production, breakdown, and excretion from sources throughout the body. It has not been validated as a way to estimate the amount of PEA, dopamine, or norepinephrine acting in your brain.

Mood and Depression

Several early depression studies focused on PAA. In one report, 144 people with major depression excreted about 45% less urinary PAA than 48 healthy volunteers. Other small studies also reported lower PAA, although a separate study found no difference in a group with unipolar depression. These are findings about a different molecule.

A study of urinary PEA included 53 hospitalized people with depression and 16 controls. It did not support a general PEA shortage in depression. Some participants with depression had unusually high excretion, and PEA and PAA were not correlated in the subgroup tested for both.

Another study measured urinary PEA in 32 healthy volunteers. Higher PEA was associated with higher hypomania questionnaire scores and lower depression scores in the female subgroup. This was an association with questionnaire scores in healthy people, and it did not establish a diagnostic test or show that changing PEA changes mood.

Taken together, these studies do not establish that low urinary PEA causes depression or that a higher result is healthier. Depression is assessed through symptoms, their duration, and their effect on daily life.

Psychosis and Bipolar Disorder

Older studies of urinary PEA in schizophrenia disagreed. Differences in study populations and laboratory methods limit comparisons.

A case series described five women with bipolar disorder who had fluctuating, sometimes high urinary PEA and episodes of unusual behavior and psychosis. This small, selected group cannot establish that urinary PEA predicts episodes or measures bipolar illness severity.

A separate blood study found lower plasma PEA in the paranoid schizophrenia subgroup, with no clear difference between the full schizophrenia group and controls. Plasma and urine are different measurements. Opposing results across studies do not establish that urinary PEA is a reliable marker of your current psychiatric state.

Tics and Tourette Syndrome

One study compared 28 medication-free people with Tourette syndrome with 20 controls. It used 24-hour urine collections and an older laboratory method. Half of the Tourette group had free urinary PEA below the lowest value in that study's controls, and lower values were associated with greater severity on some symptom measures.

A follow-up analysis associated lower urinary PEA with worse performance on some thinking and memory tests. These observations raised a hypothesis about a subgroup with altered PEA metabolism. They have not established a urine test for diagnosing Tourette syndrome, predicting risk in family members, or guiding treatment.

What Blood Studies Add

Studies using serum have explored other associations. Serum is the liquid left after blood clots. In two groups with symptomatic knee osteoarthritis, higher serum PEA was associated with greater knee pain. The research also examined relationships with inflammatory signals. These findings concern serum PEA and do not validate urinary PEA as a pain or inflammation marker.

A small study comparing 22 people with sepsis and 10 healthy volunteers identified serum PEA as a possible marker. Its ability to separate those groups scored 0.825 on a research discrimination scale where 1 represents perfect separation. That is not the percentage of people correctly diagnosed, and the study did not establish performance in an independent group or evaluate this urine test.

What Serial Results Can Establish

Repeated measurements can describe changes in urinary excretion. There is no validated amount of change that signals improvement, deterioration, or a need to change treatment. A trend also cannot resolve the uncertain relationship between urine and brain chemistry.

When Results Can Be Misleading

• Medication effects: a placebo-controlled crossover study in 12 boys with attention deficit disorder found that d-amphetamine raised urinary PEA. The change did not predict clinical response. Human studies also found increased urinary PEA during selegiline treatment. These drug effects can occur without indicating a new psychiatric condition.
• Collection timing: small older studies disagreed about a daily rhythm in urinary PEA. A spot sample and a full-day collection cover different periods, which limits comparisons.
• Urine dilution: if the laboratory divides PEA by creatinine, the adjustment can be influenced by muscle mass and kidney function as well as hydration. Creatinine is a waste product of muscle metabolism. The ratio is not a direct measure of brain production.
• LC-MS limitations: other substances in urine can weaken or strengthen the instrument signal. Sample preparation, separation of similar compounds, calibration, and storage all need appropriate laboratory controls. LC-MS does not by itself guarantee that two laboratories produce interchangeable results.

A value outside a laboratory's comparison interval does not establish a deficiency or excess in your brain. Interpretation depends on the assay, the collection, and your medication history; there is no established PEA-based decision pathway for psychiatric care.